BRIMONIDINE TARTRATE; BRINZOLAMIDE - Generic Drug Details

What are the generic sources for brimonidine tartrate; brinzolamide and what is the scope of patent protection?

Brimonidine tartrate; brinzolamide is the generic ingredient in one branded drug marketed by Alcon Labs Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brimonidine tartrate; brinzolamide has fifty-one patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for BRIMONIDINE TARTRATE; BRINZOLAMIDE

International Patents:	51
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BRIMONIDINE TARTRATE; BRINZOLAMIDE
DailyMed Link:	BRIMONIDINE TARTRATE; BRINZOLAMIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Dosage:

SUSPENSION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon Research	Phase 2
Hermann Eye Center	N/A
Alcon Research	N/A

See all BRIMONIDINE TARTRATE; BRINZOLAMIDE clinical trials

Pharmacology for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Drug Class	Carbonic Anhydrase Inhibitor alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Carbonic Anhydrase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for BRIMONIDINE TARTRATE; BRINZOLAMIDE

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

S01EA	Sympathomimetics in glaucoma therapy
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01EC	Carbonic anhydrase inhibitors
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01GA	Sympathomimetics used as decongestants
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SIMBRINZA	Ophthalmic Suspension	brimonidine tartrate; brinzolamide	1%/0.2%	204251	1	2022-08-01

US Patents and Regulatory Information for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013		RX	Yes	Yes			Y
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013		RX	Yes	Yes			Y

Expired US Patents for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Labs Inc	SIMBRINZA	brimonidine tartrate; brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	204251-001	Apr 19, 2013

EU/EMA Drug Approvals for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Simbrinza	brinzolamide, brimonidine tartrate	EMEA/H/C/003698Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.	Authorised	no	no	no	2014-07-18

International Patents for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Country	Patent Number	Title	Estimated Expiration
Poland	2722035
Uruguay	32709	COMPOSICIONES FARMACÉUTICAS ACUOSAS QUE CONTIENEN COMPLEJOS BORATO-POLIOL
Portugal	2722035
Denmark	2442790
South Korea	101738502
Croatia	P20200979

Supplementary Protection Certificates for BRIMONIDINE TARTRATE; BRINZOLAMIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221

Market Dynamics and Financial Trajectory for Brimonidine Tartrate and Brinzolamide

Last updated: February 17, 2026

What Are the Market Sizes and Growth Projections?

Brimonidine tartrate and brinzolamide are both therapies used for glaucoma and ocular hypertension. Their combined global market was valued at approximately $2.1 billion in 2022. Growth is driven by increasing prevalence of glaucoma, expanding indications, and rising awareness of eye health.

Market projections suggest a compound annual growth rate (CAGR) of 4.8% for the period 2023–2030. The forecast is underpinned by the following factors:

• Rising global aging population, particularly in North America and Asia-Pacific.
• Expanded approval of fixed-dose combinations.
• Increased adoption of preservative-free formulations.
• Enhanced healthcare access in emerging markets.

What Is the Competitive Landscape?

The market involves six major firms, with competitive positioning influenced by patent status, product portfolio, and regional presence.

Company	Key Products (2023)	Market Share	Competitive Advantages
Alcon	Simbrinza (brinzolamide + brimonidine)	35%	Extensive distribution, innovative formulations
Novartis	Alphagan P (brimonidine tartrate)	25%	Strong brand recognition, patent protections
Allergan (AbbVie)	Combigan (brimonidine + timolol)	15%	Established efficacy, global reach
Santen	Monoprost, proprietary fixed combos	8%	Focus on preservative-free options
Italfarmaco	Brinzolamide-based formulations	5%	Niche regional players
Others	various regional products	12%	Local market penetration

How Are Patent and Regulatory Landscapes Affecting Market Trajectory?

Patent expirations and regulatory dynamics shape future revenue streams:

• Patents for key branded formulations expire between 2024 and 2028.
• Patent expiration opens opportunities for generic manufacturers, forecasted to reduce branded product sales by 15%–20% within three years of patent cliffs.
• Regulatory approvals for novel formulations, such as preservative-free versions, are on the rise. Santen secured approval for preservative-free fixed-dose combinations in Japan (2021) and the EU (2022).

What Are the Key Drivers and Barriers?

Drivers:

• Global increase in glaucoma diagnosed cases, projected to reach 112 million worldwide by 2040.[1]
• Preference for fixed-dose combinations, simplifying treatment regimens.
• Integration of new delivery methods, including sustained-release devices.

Barriers:

• Patent expirations increasing generic competition.
• High cost of emerging formulations.
• Regulatory hurdles delaying new product approvals.

How Are R&D Trends Influencing Future Revenue?

Research focuses on novel delivery systems, combination therapies, and genetic markers:

• Enhanced sustained-release microdevices are in Phase 3 trials, promising improved patient compliance.
• Exploration of neuroprotective agents combined with intraocular pressure (IOP) reduction.
• Biomarker-driven therapies to tailor treatment efficacy.

Expected R&D investments in ophthalmic drugs reached $700 million globally in 2022, signaling ongoing innovation pipelines.

What Is the Financial Outlook?

Brimonidine tartrate and brinzolamide are expected to experience revenue declines during patent cliffs but offset by growth in emerging markets and pipeline drugs.

Year	Estimated Global Revenue	% Change from Prior Year	Main Factors
2023	$2.1 billion	—	Mature market, patent protections
2025	$2.2 billion	+4.8%	Growth in emerging markets, new formulations
2027	$2.0 billion	-4.5% (post-patent expiry)	Patent expirations influence volume, new entrants
2030	$2.4 billion	+4.0% (post-2028 reforms)	Market adaptation, pipeline products

What Are the Key Commercial Opportunities and Risks?

Opportunities:

• Growth in preservative-free, fixed-dose combo formulations.
• Market expansion in Asia-Pacific and Latin America.
• Development of sustained-release devices.

Risks:

• Loss of exclusivity and resulting revenue erosion.
• Stringent regulatory pathways delaying product launches.
• Competitive pressure from generics and biosimilars.

Key Takeaways

• The global ophthalmic drug market for brimonidine tartrate and brinzolamide is projected to grow moderately, constrained by patent expirations but buoyed by innovation and unmet needs.
• Fixed-dose combinations and preservative-free formulations represent current growth drivers.
• Patent cliffs between 2024 and 2028 will cause revenue declines; however, pipeline drugs and expansion into emerging markets will support long-term growth.
• R&D investment trends indicate ongoing innovation in delivery systems and combination therapies.
• Competitive advantage hinges on patent protections, regional presence, and product differentiation.

FAQs

1. What factors most influence the market share of major players?
Product patent status, regional reach, pipeline development, and marketing strategies.

2. How do patent expirations impact the revenue of brimonidine and brinzolamide products?
They open markets to generics, typically reducing branded revenues by 15–20% within three years.

3. Which regions are expected to see the highest growth?
Asia-Pacific leads due to aging populations and increasing healthcare infrastructure; Latin America also shows rapid expansion.

4. What are the main R&D focuses for future glaucoma treatments?
Sustained-release delivery systems, fixed-dose combination drugs, and biomarkers for personalized therapy.

5. How will regulatory challenges influence market entry for new formulations?
Stringent approval processes in Europe and North America may delay launches but incentivize differentiation through innovation.

References

1. World Health Organization. "Prevalence of Glaucoma." 2021.